The cardiovascular and metabolic complications of HIV infection

Area of Science:

• Cardiology
• Infectious Diseases
• Immunology

Background:

• Longer survival rates for HIV-infected patients due to effective therapies.
• Cardiovascular disease (CVD) is a growing concern in the HIV-infected population globally.
• HIV-associated CVD contributes significantly to healthcare costs.

Purpose of the Study:

• To highlight the increased frequency and severity of cardiovascular complications in HIV infection.
• To discuss the pathogenesis of HIV-related cardiovascular disorders.
• To emphasize the need for further research in understanding and managing these conditions.

Main Methods:

• Review of existing literature on cardiovascular complications in HIV infection.
• Analysis of the impact of HIV, opportunistic infections, viral proteins (gp120, Tat), and cytokines on cardiovascular health.
• Examination of the role of antiretroviral therapies, including protease inhibitors, in inducing metabolic changes (lipodystrophy, dyslipidemia) that affect cardiovascular risk.

Main Results:

• HIV-infected patients exhibit increased incidence of pericarditis, myocarditis, cardiomyopathy, coronary vasculopathy, arterial aneurysms, pulmonary hypertension, and endocarditis.
• Cardiomyopathy, pericardial tamponade, endocarditis, and vasculopathy are associated with poor prognosis and fatal outcomes.
• Protease inhibitors can lead to lipodystrophy, dyslipidemia, and insulin resistance, accelerating atherosclerosis.

Conclusions:

• Cardiovascular disease is a major cause of morbidity and mortality in the HIV-infected population.
• Multiple factors, including HIV itself, opportunistic infections, viral proteins, cytokines, and antiretroviral drug side effects, contribute to HIV-associated cardiovascular pathology.
• Further basic and clinical research is essential for elucidating pathogenesis and developing effective management strategies for cardiovascular complications in HIV patients.